From Name:
From Email:
To Name:
To Email:

Optional Message:

Special study targeting cancer surveillance in CoC-accredited programs launches April 17

from ACS-CRP

Prostate cancer is the most common cancer in men, currently affecting around 3 million American survivors, with another 180,000 men diagnosed each year. After prostate cancer treatment, prostate-specific antigen (PSA) testing is the standard method for surveillance and early detection of recurrence. It is unknown how often PSA surveillance testing is needed. Optimizing post-treatment surveillance was identified as the highest priority topic by patients, clinicians and policy makers in a stakeholder-driven research prioritization effort based on its impact, uncertainty about the optimal approach and potential to significantly change practice.

In order to achieve the intended impact on clinical practice and benefit to patients, a Commission on Cancer (CoC) Special Study will launch April 17 to investigate post-treatment surveillance and recurrence after prostate cancer treatment. Participation in this special study is required by all CoC-accredited sites to fulfill Standard 5.7 – Commission on Cancer Special Studies (with the exception of Veterans Affairs/Department of Defense facilities, pediatric facilities and facilities with a reference date after Jan. 1, 2008). The deadline for data submission is July 17. Send any questions or comments to more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063